(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/032226 A1

(51) International Patent Classification:
A61K 38/00 (2006.01) *C12N 15/11* (2006.01)
A61K 48/00 (2006.01) *C12N 15/113* (2010.01)
C12N 15/09 (2006.01) *C12N 15/63* (2006.01)

(21) International Application Number:
PCT/US2021/045220

(22) International Filing Date:
09 August 2021 (09.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/063,032 07 August 2020 (07.08.2020) US

(71) Applicant: **SPACECRAFT SEVEN, LLC** [US/US]; 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US).

(72) Inventors: **HERZOG, Christopher Dean**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **SACRAMENTO, Chester Bittencort**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **PRABHAKAR, Raj**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **RICKS, David**; c/o Spacecraft Seven, LLC, 9 Cedar Brook Drive, Cranbury, New Jersey 08512 (US).

(74) Agent: **LAHERTY, Carol D.** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: PLAKOPHILIN-2 (PKP2) GENE THERAPY USING AAV VECTOR



FIG. 1

(57) Abstract: Provided herein is a gene therapy for PKP2 (Plakophilin-2), *e.g.* using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.

WO 2022/032226 A1